PUBLISHER: The Business Research Company | PRODUCT CODE: 1938714
PUBLISHER: The Business Research Company | PRODUCT CODE: 1938714
Veterinary biomarkers are measurable indicators used to diagnose, monitor, and manage diseases in animals. These can include biological molecules such as proteins, genes, or metabolites that reflect a specific physiological or pathological state. Veterinary biomarkers are essential for early disease detection, evaluating treatment efficacy, and understanding disease mechanisms.
The primary types of veterinary biomarkers include biomarkers themselves, kits and reagents, and biomarker readers. Biomarkers are specific biological molecules or substances used to detect, diagnose, and monitor health conditions in animals. These biomarkers, present in blood, urine, or other body fluids, provide important insights into an animal's health status. They are used for various diseases, including inflammatory and infectious diseases, cardiovascular diseases, skeletal muscle diseases, tumors, and more. Applications of these biomarkers span disease diagnostics, preclinical research, and other areas, affecting both companion and production animals.
Tariffs have affected the veterinary biomarkers market by raising costs for imported kits, reagents, and biomarker readers. Segments such as ELISA kits, PCR kits, and optical or fluorescence readers are most impacted, particularly in North America and Europe. While tariffs increase operational costs, they encourage local manufacturing, promote innovation in cost-effective biomarker solutions, and accelerate the adoption of domestic diagnostic technologies.
The veterinary biomarkers market research report is one of a series of new reports from The Business Research Company that provides veterinary biomarkers market statistics, including veterinary biomarkers industry global market size, regional shares, competitors with a veterinary biomarkers market share, detailed veterinary biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary biomarkers industry. This veterinary biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The veterinary biomarkers market size has grown rapidly in recent years. It will grow from $0.91 billion in 2025 to $1.02 billion in 2026 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to reliance on conventional diagnostics, limited biomarker availability, growing prevalence of animal diseases, traditional veterinary research methods, low adoption of preclinical research tools.
The veterinary biomarkers market size is expected to see rapid growth in the next few years. It will grow to $1.61 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to advancement in biomarker discovery, increasing investment in veterinary diagnostics, rising awareness of animal health monitoring, growth of companion and production animal segments, adoption of automated biomarker readers and digital platforms. Major trends in the forecast period include expansion of diagnostic biomarker development, growth in predictive and prognostic biomarker applications, increasing adoption of elisa, pcr, and rapid test kits, rising use of advanced biomarker readers and analytical devices, growing focus on companion and production animal health.
The rising pet ownership is expected to drive the growth of the veterinary biomarkers market going forward. Pet ownership refers to the state of having one or more animals as companions, where individuals provide care, shelter, and attention to meet their pets' needs and well-being. The increase in pet ownership is attributed to factors such as the desire for companionship, the benefits of pet therapy, and growing awareness of the positive impact pets have on mental and physical health. Veterinary biomarkers support pet ownership by monitoring animal health, enabling early disease detection, and facilitating personalized treatment plans. For example, in June 2025, according to Petfood Industry, a US-based leading resource for pet food and treat manufacturers, 94 million U.S. households owned at least one pet, up from 82 million in 2023, reflecting a significant rise in pet ownership and growing demand for pet care products and services. Therefore, the increase in pet ownership is driving the growth of the veterinary biomarkers market.
Leading players in the veterinary biomarkers market are focusing on strategic partnerships to strengthen their competitive position. Strategic partnerships involve collaborations among companies, research institutions, and veterinary practices to advance the development and application of diagnostic tools. For example, in November 2025, Bionote USA, a US-based veterinary diagnostics company, launched the Vcheck C1 In-Clinic Chemistry Analyzer, an affordable and compact biochemistry testing device designed to expand point-of-care biomarker and diagnostic capabilities in veterinary practices. The Vcheck C1 enables simultaneous analysis of up to 24 biochemical parameters from small animal samples in 10-12 minutes, delivering laboratory-grade accuracy with a simplified workflow. It supports testing across 34 species, including canine, feline, equine, and bovine patients, with validated reference ranges for each species. Featuring broad test panels such as comprehensive chemistry, electrolyte, liver, kidney, and diabetes profiles, the analyzer helps clinicians quickly diagnose and monitor health conditions without sending samples to external laboratories. Its affordable pricing and multi-species support enhance access to rapid, in-clinic biomarker diagnostics across a wide range of veterinary settings.
In November 2025, Zoetis Inc., a US-based provider of animal health medicines, vaccines, diagnostics, and technology solutions, acquired Veterinary Pathology Group (VPG) for an undisclosed amount. Through this acquisition, Zoetis aimed to expand its veterinary diagnostics portfolio, enhancing its ability to provide advanced biomarker and pathology testing solutions to veterinarians in the UK and Ireland while strengthening its global diagnostic footprint. Veterinary Pathology Group is a UK- and Ireland-based provider of comprehensive laboratory diagnostic services supporting biomarker-based testing for disease detection and monitoring in animal health.
Major companies operating in the veterinary biomarkers market are Thermo Fisher Scientific Inc., Zoetis Inc., IDEXX Laboratories Inc., Antech Diagnostics Inc., Neogen Corporation, Heska Corporation, Olink Proteomics, SomaLogic, Life Diagnostics Inc., INDICAL BIOSCIENCE GmbH., Mercodia AB, Bionote USA Inc., Acuvet Biotech, Alertix Veterinary Diagnostics AB., MI:RNA Diagnostics Ltd., Veterinary Biomarkers Inc., Vetmaya Healthcare Private Limited, VolitionRx, BioVet Diagnostics, Randox Laboratories Ltd., Bio-Rad Laboratories Inc., QIAGEN N.V., FidoCure, Scil Animal Care Company GmbH, Shenzhen Mindray Animal Medical Technology Co. Ltd., Esaote SPA, Innovative Diagnostics SAS, Ayoxxa Biosystems
North America was the largest region in the veterinary biomarkers market in 2025. The regions covered in the veterinary biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the veterinary biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The veterinary biomarkers market consists of sales of biomarker research tools, imaging biomarkers, diagnostic kits, and immunoassays. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Veterinary Biomarkers Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses veterinary biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for veterinary biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The veterinary biomarkers market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.